Diagnosis, Biomarkers, and Treatment of Metabolic Disorders

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 766

Special Issue Editor


E-Mail Website
Guest Editor
Glycosphingolipid and Glycoprotein Disorders Unit, Medical Genetic Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
Interests: lysosomal storage diseases; neurodegenerative diseases; genomics; genetic engineering; cancer biomarkers; metabolism

Special Issue Information

Dear Colleagues,

Diagnosis, Biomarkers, and Treatment of Metabolic Disorders is a Special Issue published in the Journal Diagnostics (ISSN 2075-4418) which is an international scholarly open-access journal. It publishes original research articles and comprehensive reviews, and there is no restriction on the maximum length of the papers. Our aim is to encourage healthcare professionals and scientists to publish their experimental, theoretical, and original research related to any aspects of metabolic diseases in humans or animal models in as much detail as possible. Full experimental and/or methodological details must be provided for research articles. This includes clinical, experimental, genetic, biochemical, methodological, theoretical, ethical, and counseling aspects.

The scope of this Special Issue includes as follows:

  • Metabolic diseases;
  • Treatment and therapies of metabolic diseases;
  • Diagnosis of metabolic diseases;
  • Biomarkers of metabolic diseases;
  • Inherited metabolic diseases;
  • Inborn errors of metabolism;
  • Neurodegeneration in metabolic diseases;
  • Lysosomal storage diseases;
  • Pathogenesis of metabolic diseases;
  • Artificial intelligence and machine learning in inherited metabolic diseases;
  • Functional genomics of metabolic diseases.

Welcome to submit your related work to the Special Issue.

Dr. Elena-Raluca Nicoli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic disorders
  • diagnosis
  • treatment
  • biomarkers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2566 KiB  
Article
Diagnostic Accuracy of the Triglyceride–Glucose Index (TyG), TyG Body Mass Index, and TyG Waist Circumference Index for Liver Steatosis Detection
by Alejandra Mijangos-Trejo, Raúl Gómez-Mendoza, Martha Helena Ramos-Ostos, Graciela Castro-Narro, Misael Uribe, Eva Juárez-Hernández and Iván López-Méndez
Diagnostics 2024, 14(7), 762; https://doi.org/10.3390/diagnostics14070762 - 3 Apr 2024
Viewed by 571
Abstract
Background: The triglyceride–glucose index (TyG) and a combination of body mass index (BMI) and waist circumference (WC) have been proposed as predictive scores for liver steatosis (LS). The aim of this study was to determine the diagnostic accuracy of these indices compared with [...] Read more.
Background: The triglyceride–glucose index (TyG) and a combination of body mass index (BMI) and waist circumference (WC) have been proposed as predictive scores for liver steatosis (LS). The aim of this study was to determine the diagnostic accuracy of these indices compared with controlled attenuation parameters (CAPs) and other predictive scores of LS. Methods: A retrospective analysis of patients who attended a check-up unit in 2021 was performed. LS was determined by CAP. Anthropometric and biochemical parameters for calculating TyG, TyG-BMI, TyG-WC, fatty liver index, and hepatic steatosis index were obtained. ROC curve was used to establish the best cut-off point of each TyG index for LS detection. The accuracy was determined for all patients, as well as for overweight and diabetic patients. Results: Medical records of 855 patients with a median age of 48 [IQR, 44–54] years and a BMI of 25.7 [IQR 23.4–28.1] kg/m2 were included. According to CAP, LS prevalence was 31.8% (n = 272). TyG-BMI and TyG-WC show better AUCs compared with CAP (0.82, 0.81), FLI (0.96, both), and HSI (0.93, 0.85). For diabetic patients, TyG-WC shows an AUC of 0.70. Meanwhile, TyG-BMI shows better accuracy (0.75) compared with CAP. Conclusions: TyG-BMI and TyG-WC showed a superior predictive accuracy for detecting LS compared with the TyG index. Full article
(This article belongs to the Special Issue Diagnosis, Biomarkers, and Treatment of Metabolic Disorders)
Show Figures

Figure 1

Back to TopTop